1. SLAMF1 is expressed and secreted by hepatocytes and the liver in nonalcoholic fatty liver disease
- Author
-
Oscar Gomez-Torres, Shripa Amatya, Lilly Kamberov, Hemangini A. Dhaibar, Pranshu Khanna, Oren Rom, Arif Yurdagul, A. Wayne Orr, Kelly Nunez, Paul Thevenot, Ari Cohen, Hrishikesh Samant, Jonathan S. Alexander, Emma Burgos-Ramos, Adrian Chapa-Rodriguez, and Diana Cruz-Topete
- Subjects
Liver Cirrhosis ,Mice ,Hepatology ,Liver ,Signaling Lymphocytic Activation Molecule Family Member 1 ,Physiology ,Non-alcoholic Fatty Liver Disease ,Signaling Lymphocytic Activation Molecule Family ,Physiology (medical) ,Gastroenterology ,Hepatocytes ,Animals ,Humans - Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver disease in the United States and worldwide. Nonalcoholic steatohepatitis (NASH), the most advanced form of NAFLD, is characterized by hepatic steatosis associated with inflammation and hepatocyte death. No treatments are currently available for NASH other than lifestyle changes, and the disease lacks specific biomarkers. The signaling lymphocytic activation molecule family 1 (SLAMF1) protein is a self-ligand receptor that plays a role in orchestrating an immune response to some pathogens and cancers. We found that livers from humans and mice with NASH showed a more prominent immunohistochemistry staining for SLAMF1 than non-NASH controls. Furthermore, SLAMF1 levels are significantly increased in NASH plasma samples from mice and humans compared with their respective controls. In mice, the levels of SLAMF1 correlated significantly with the severity of the NASH phenotype. To test whether SLAMF 1 is expressed by hepatocytes, HepG2 cells and primary murine hepatocytes were treated with palmitic acid (PA) to induce a state of lipotoxicity mimicking NASH. We found that PA treatments of HepG2 cells and primary hepatocytes lead to significant increases in SLAMF1 levels. The downregulation of SLAMF1 in HepG2 cells improved the cell viability and reduced cytotoxicity. The in vivo data using mouse and human NASH samples suggests a potential role for this protein as a noninvasive biomarker for NASH. The in vitro data suggest a role for SLAMF1 as a potential therapeutic target to prevent hepatocyte death in response to lipotoxicity.
- Published
- 2023